Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study

Ozaki, Kai; Narita, Shintaro; Hata, Kenichi; Yanagisawa, Takafumi; Tanaka, Toshikazu; Togashi, Kyo; Hamaya, Tomoko; Okamoto, Teppei; Yamamoto, Hayato; Yoneyama, Takahiro; Hashimoto, Yasuhiro; Kimura, Takahiro; Habuchi, Tomonori; Οhyama, Chikara

doi:10.1007/s00345-022-04237-3

Cited by 2 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Upfront DOC is a cost-effective option for eligible men with mHSPC per a Japanese study with 340 patients treated with either upfront DOC or upfront ABI. Though there was no significant difference in PFS, the medical costs were lower in the DOC group ($1239) than the ABI group ($3453) [ 14 ▪ ].…”

Section: Treatment Intensification and Triplet Therapy: Implications ...mentioning

confidence: 99%

“…The association between baseline body mass index (BMI) and metformin exposure with quality of life (QOL) and PCa outcomes including survival in patients enrolled in the CHAARTED trial has been evaluated in 788 patients [ 14 ▪ ]. Lower BMI was associated with high volume disease and poorer baseline QOL on functional assessment of cancer therapy-prostate.…”

Section: Treatment Intensification and Triplet Therapy: Implications ...mentioning

confidence: 99%

“…Metformin exposure was not associated with survival in the small exploratory multivariable analysis. Overall, the study did not find a link between baseline BMI and survival, but lower baseline BMI was associated with features of greater cancer burden and poorer QOL [ 14 ▪ ].…”

Section: Treatment Intensification and Triplet Therapy: Implications ...mentioning

confidence: 99%

See 2 more Smart Citations

Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions

Zattoni,

Rajwa,

Gandaglia

2023

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of review To evaluate the evidence supporting treatment intensification in mHSPC, with a focus on possible indications for treatment in each clinical setting. Recent findings There is a growing armamentarium of treatment options for patients with metastatic hormone-sensitive prostate cancer (mHSPC). These include combinations of treatments such as androgen deprivation therapy (ADT), docetaxel, and new antiandrogenic therapies. Treatment intensification with chemotherapy or newer hormonal agents may improve patient's oncologic outcomes, but it can also come with additional toxicities and costs. Therefore, we need to take into account individual patient factors and preferences when deciding on the optimal combination therapy. Additionally, ongoing research is needed to identify biomarkers and new image techniques that can predict response to treatment and identify the best candidate for each treatment. Summary Challenges and unanswered questions regarding treatment intensification and de-intensification are still present. Further studies are still needed to identify which patients would benefit most from this approach to improve quality of life without compromising overall survival outcomes.

show abstract

Section: Treatment Intensification and Triplet Therapy: Implications ...mentioning

confidence: 99%

Section: Treatment Intensification and Triplet Therapy: Implications ...mentioning

confidence: 99%

See 1 more Smart Citation

Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions

Zattoni,

Rajwa,

Gandaglia

2023

Current Opinion in Urology

View full text Add to dashboard Cite

show abstract

Initial treatment and resource utilization among patients with metastatic-castration sensitive prostate cancer in Japan: a retrospective real-world study

Kimura,

Ito,

Taguchi

et al. 2024

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objectives The introduction of novel drugs for metastatic castration-sensitive prostate cancer has expanded treatment options for patients. Associated changes in healthcare resource utilization may have occurred in tandem, but nationwide information is limited. This study aimed to describe initial treatment patterns and healthcare resource utilization (including costs) for patients with metastatic castration-sensitive prostate cancer in routine clinical practice in Japan. Methods This retrospective, longitudinal cohort study used a large-scale claims database covering acute care hospitals of various sizes. Included were men who received first medical treatment for metastatic castration-sensitive prostate cancer between January 2015 and July 2021 (identification period). The primary endpoint was the initial treatment pattern for metastatic castration-sensitive prostate cancer. Results Among 7665 men with metastatic castration-sensitive prostate cancer, the median (Q1, Q3) duration of first-line therapy was 8.2 (3.4, 17.3) months. During the overall period between 2015 and 2021, the most common initial pharmacotherapy (88.1% of treatment regimens) was ‘combined androgen blockade or androgen deprivation therapy only or first-generation anti-androgen only’. Use of androgen receptor signaling inhibitors increased following their introduction in 2018, reaching 26.6% of treatments started in 2021 (abiraterone + androgen deprivation therapy 9.4%, apalutamide + androgen deprivation therapy 9.2%, enzalutamide + androgen deprivation therapy 8.0%). Median total healthcare-related cost per person-year was JPY 244 479, with metastatic castration-sensitive prostate cancer drugs accounting for approximately one-third of the cost (JPY 396 620). Conclusions Since androgen receptor signaling inhibitors were introduced, treatment patterns in patients with metastatic castration-sensitive prostate cancer in Japan have shifted, with an increased trend toward prescription of these agents. However, the most frequently used regimen for first-line treatment continues to be ‘combined androgen blockade or androgen deprivation therapy only or first-generation anti-androgen only’.

show abstract

Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study

Cited by 2 publications

References 29 publications

Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions

Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions

Initial treatment and resource utilization among patients with metastatic-castration sensitive prostate cancer in Japan: a retrospective real-world study

Contact Info

Product

Resources

About